All In Biotech

Drug Trial Radar · NCT06291376

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 584 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

584

Actual

Start

Mar 29, 2024

Primary completion

Jan 5, 2026

Study completion Jul 18, 2030

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Conditions

  • Immunoglobulin A Nephropathy
  • IgAN

Interventions

  • RavulizumabDrug

    Participants will receive ravulizumab via weight-based intravenous (IV) infusion.

  • PlaceboDrug

    Participants will receive placebo via weight-based IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR) at Week 34Time frame: Baseline, Week 34
  2. Change from Baseline in Glomerular Filtration Rate (eGFR) at Week 106Time frame: Baseline, Week 106

Locations

246 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Alabaster, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Bernardino, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Stanford, California

  • Research Site

    Torrance, California

  • Research Site

    Valencia, California

  • Research Site

    Bay Pines, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Acworth, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Kansas City, Missouri

  • Research Site

    North Las Vegas, Nevada

  • Research Site

    Albany, New York

  • Research Site

    New York, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Arlington, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Shenandoah, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Ciudad de Buenos Aires, Argentina

Showing 40 of 246 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.